Key Quantitative Figures
- Amount Raised: ₹53,56,82,326.93 (via preferential issue on April 24, 2025)
- Funds Utilized: ₹29,29,82,326.93
- Unutilized Amount: ₹24,27,00,000.00 (calculated as difference between raised and utilized amounts)
Dates and Regulatory References
- Fund Raising Date: April 24, 2025
- Reporting Period: Quarter and year ended March 31, 2026
- Audit Committee Review Date: May 27, 2026
- Filing Date: May 28, 2026
- Regulatory References: SEBI LODR Regulation 32, SEBI Circular CIR/CFD/CMD1/162/2019
Parties Involved
- Listed Entity: Medicamen Biotech Limited
- Stock Exchanges: BSE Limited (Scrip Code: 531146) and National Stock Exchange of India Ltd (Symbol: MEDICAMEQ)
- Reviewing Authority: Audit Committee of the Company
Fund Utilization Details
Original Objects for Fund Utilization:
- Drug Development of 50 SKUs for Regulated markets
- Registration of dossiers, etc.
- Meet the Enhanced working capital requirements
- Capital expenditure in some area of upgradation of the existing facilities
- Expansion of operations in Domestic Market
- General Corporate Purposes
Utilization Status:
- No deviation or variation in the utilization of funds
- No modification to original objects or allocations
- Monitoring agency was not applicable for this fund raising
Audit Committee Findings
The Audit Committee reviewed the utilization on May 27, 2026 and concluded: "There is no deviation/variation in the utilization of funds."
Financial Impact Assessment
The disclosure confirms that the company has utilized ₹29.30 crore of the ₹53.57 crore raised, representing approximately 54.7% utilization of the total funds raised. The remaining ₹24.27 crore remains unutilized but within the original intended purposes. No financial impact from deviation is reported.